Mesa Laboratories, Inc.
MLAB
$98.67
$2.312.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 240.98M | 237.75M | 228.38M | 223.71M | 216.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 240.98M | 237.75M | 228.38M | 223.71M | 216.19M |
| Cost of Revenue | 88.88M | 86.27M | 83.26M | 82.39M | 81.71M |
| Gross Profit | 152.10M | 151.48M | 145.12M | 141.32M | 134.48M |
| SG&A Expenses | 115.02M | 111.27M | 111.53M | 111.39M | 111.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 223.41M | 217.17M | 213.65M | 213.00M | 212.50M |
| Operating Income | 17.57M | 20.58M | 14.73M | 10.71M | 3.69M |
| Income Before Tax | 5.96M | -269.83M | -265.67M | -270.81M | -275.65M |
| Income Tax Expenses | 7.94M | -20.39M | -20.02M | -20.50M | -21.40M |
| Earnings from Continuing Operations | -1.97 | -249.44 | -245.65 | -250.31 | -254.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.97M | -249.44M | -245.65M | -250.31M | -254.25M |
| EBIT | 17.57M | 20.58M | 14.73M | 10.71M | 3.69M |
| EBITDA | 42.10M | 43.90M | 41.61M | 39.61M | 35.26M |
| EPS Basic | -0.36 | -46.25 | -45.54 | -46.41 | -47.14 |
| Normalized Basic EPS | 0.46 | 0.46 | 0.94 | 0.29 | 0.01 |
| EPS Diluted | -0.37 | -46.26 | -45.56 | -46.42 | -47.14 |
| Normalized Diluted EPS | 0.46 | 0.45 | 0.93 | 0.29 | 0.01 |
| Average Basic Shares Outstanding | 21.68M | 21.63M | 21.60M | 21.57M | 21.55M |
| Average Diluted Shares Outstanding | 21.76M | 21.72M | 21.69M | 21.60M | 21.55M |
| Dividend Per Share | 0.64 | 0.64 | 0.64 | 0.64 | 0.64 |
| Payout Ratio | -175.68% | -1.39% | -1.41% | -1.38% | -1.36% |